Elaboration and use of syngenic pre-clinical models for cancer drug development
Active Awarded Last action
- Contract number
- 75N91021F00017
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $21,659,702
Award facts
- Contract value 100% obligated
- $21,659,701.83 Current and potential, with all options
- Completion date 64% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $11,687,558 | |
| Terminate for Convenience | -$2,177,307 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $12,149,451 |
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 16, 2021, with a ceiling value of $21.659 million for elaboration and use of syngenic pre-clinical models for cancer drug development, with ultimate completion on August 21, 2029.
Place of performance is Frederick, MD. The order is priced on a cost-plus-fixed-fee basis. Per Service Contract Inventory reporting, this delivery order has grown significantly in labor footprint and invoiced value. FY2025 reflects 9.5 FTEs and $2.7 million invoiced; FY2024 recorded 2.0 FTEs and $483 thousand invoiced; FY2023 showed 0.5 FTEs and $127 thousand invoiced. Derived government-paid hourly rates rose from $110.35 per hour in FY2022 to $132.39 per hour in FY2023, moderating to $118.73 per hour in FY2024. In FY2025, Leidos Biomedical Research self-performed all reported hours with no subcontractors.
Quick answers
Who was awarded contract 75N91021F00017?
75N91021F00017 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2021.
How much is contract 75N91021F00017 worth?
The government has obligated $21,659,702 on 75N91021F00017.
Is contract 75N91021F00017 an order under another contract?
Yes. 75N91021F00017 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91021F00017 competed?
The extent of competition for 75N91021F00017 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award